Citing a 2016 case where Mylan, the maker of the branded epinephrine autoinjector EpiPen, paid the government hundreds of millions of dollars to settle the company’s failure to adequately pay Medicaid rebates, 2 senators introduced a bipartisan bill that attempts to prevent similar issues.
Citing a 2016 case where Mylan, the maker of the branded epinephrine autoinjector EpiPen, paid the government hundreds of millions of dollars to settle the company’s failure to adequately pay Medicaid rebates, 2 senators introduced a bipartisan bill that attempts to prevent similar issues.
Senate Finance Committee Ranking Member Ron Wyden, D-Oregon, and Senator Chuck Grassley, R-Iowa, the senior member of the committee, introduced a bill called the Right Rebate Act, aiming to give Medicaid more tools to go after drug manufacturers when they are suspected of misclassifying a drug as generic when it should be brand name. They said the bill would fix an issue in Medicaid that has allowed pharmaceutical manufacturers to misclassify their drugs and overcharge taxpayers by hundreds of millions of dollars.
In 2016, Mylan was found to have drastically increased prices since it began selling the emergency allergy treatment it acquired, but did not develop, in 2007. A series of price increases (more than 500% total) led to a $608.61 price for a 2-pack of the device.
Drug companies pay rebates of 13% for generics and 23.1% for brand name drugs, which gives the government some savings, albeit far less than would be the case if the government could use its market power to negotiate discounts.
Mylan classified the EpiPen as a generic and paid the smaller rebate for $960 million worth of product purchased between 2011 and 2015. This happened as Mylan was charging consumers and health plans ever-increasing prices for the pens as brand name products, based not on the epinephrine drug itself but on the design of the autoinjector.
Without admitting any fault, Mylan settled with the federal government for $465 million.
Under the proposed bill, HHS would have the authority to reclassify drugs, impose civil monetary penalties, and recover incorrect rebate payments. It would also create oversight mechanisms. HHS would have to tell Congress about how its new authorities have been used and the actions that have been taken to reclassify drugs.
“While families struggle to afford medicines like EpiPen, drug makers are busy manipulating the system to squeeze taxpayers even more,” Wyden said in a statement. “This bipartisan bill will crack down on Big Pharma’s games and help prevent them from taking advantage of Medicaid, a program meant to protect the most vulnerable. I am hopeful that this legislation will become law by the end of the year and set the tone for the important work that lies ahead to lower prescription drug prices for families across the country.”
“Misclassification of prescription drugs hurts millions of Americans whose lives depend on those medications, such as EpiPen, but can’t afford them due to unnecessarily exorbitant pricing,” Grassley said. “This legislation is a significant step forward to fixing the problems in our health care system that have allowed pharmaceutical manufacturers to price gouge taxpayers and consumers for too long.”
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More